GSA Capital Partners LLP Acquires 47,824 Shares of Azenta, Inc. $AZTA

GSA Capital Partners LLP increased its holdings in shares of Azenta, Inc. (NASDAQ:AZTA) by 482.7% during the fourth quarter, Holdings Channel reports. The fund owned 57,731 shares of the company’s stock after purchasing an additional 47,824 shares during the period. GSA Capital Partners LLP’s holdings in Azenta were worth $1,920,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of AZTA. Integrated Wealth Concepts LLC bought a new stake in Azenta during the 1st quarter worth approximately $435,000. Millennium Management LLC grew its position in Azenta by 214.8% during the 1st quarter. Millennium Management LLC now owns 340,580 shares of the company’s stock worth $11,798,000 after acquiring an additional 232,405 shares during the last quarter. Empowered Funds LLC grew its position in Azenta by 10.5% during the 1st quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock worth $225,000 after acquiring an additional 618 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Azenta by 17.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 201,337 shares of the company’s stock worth $6,974,000 after acquiring an additional 30,492 shares during the last quarter. Finally, Creative Planning bought a new position in Azenta in the 2nd quarter worth approximately $270,000. 99.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on AZTA shares. Evercore dropped their price objective on shares of Azenta from $50.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Weiss Ratings cut shares of Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. TD Cowen restated a “hold” rating on shares of Azenta in a research report on Wednesday, February 4th. Zacks Research upgraded shares of Azenta from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Finally, Needham & Company LLC dropped their price objective on shares of Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Azenta has an average rating of “Hold” and an average price target of $39.50.

Azenta Stock Performance

Shares of Azenta stock opened at $17.65 on Wednesday. The firm has a fifty day moving average of $21.80 and a two-hundred day moving average of $29.25. The stock has a market capitalization of $813.49 million, a price-to-earnings ratio of -4.46 and a beta of 1.43. Azenta, Inc. has a 52 week low of $15.93 and a 52 week high of $41.73.

Azenta (NASDAQ:AZTA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.16). The business had revenue of $144.80 million for the quarter, compared to the consensus estimate of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 EPS.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.